NCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT03003195 2024-09-03
The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients
University of Arkansas
Phase 2 Withdrawn
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03939234 2022-02-21
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
Herlev Hospital
Phase 2 Completed
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00184067 2014-05-21
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
University of Southern California
Phase 2 Terminated